Danaher Corporation $DHR Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. lessened its holdings in Danaher Corporation (NYSE:DHR) by 33.5% during the first quarter, HoldingsChannel.com reports. The fund owned 34,512 shares of the conglomerate’s stock after selling 17,355 shares during the quarter. Pacer Advisors Inc.’s holdings in Danaher were worth $6,543,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Elevated Capital Advisors LLC acquired a new position in shares of Danaher during the fourth quarter worth about $26,000. Hilton Head Capital Partners LLC purchased a new stake in shares of Danaher in the fourth quarter worth about $27,000. Clal Insurance Enterprises Holdings Ltd grew its stake in shares of Danaher by 71.6% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock valued at $29,000 after buying an additional 53 shares in the last quarter. JPL Wealth Management LLC purchased a new stake in shares of Danaher during the 3rd quarter valued at about $25,000. Finally, Main Street Group LTD purchased a new stake in shares of Danaher during the 1st quarter valued at about $25,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Price Performance

Shares of NYSE DHR opened at $199.52 on Thursday. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The business has a 50 day moving average price of $189.84 and a two-hundred day moving average price of $194.50. The firm has a market cap of $140.26 billion, a PE ratio of 35.44, a price-to-earnings-growth ratio of 2.43 and a beta of 0.78.

Danaher (NYSE:DHR) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.Danaher’s quarterly revenue was up 5.5% on a year-over-year basis. During the same period in the prior year, the company posted $0.77 EPS. Sell-side analysts expect that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DHR has been the topic of several recent research reports. Royal Bank Of Canada boosted their price target on Danaher from $200.00 to $215.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 22nd. Stifel Nicolaus dropped their price objective on shares of Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. HSBC reduced their target price on shares of Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Morgan Stanley decreased their target price on shares of Danaher from $270.00 to $255.00 and set an “overweight” rating for the company in a research note on Wednesday, April 22nd. Finally, Piper Sandler began coverage on shares of Danaher in a report on Thursday, June 11th. They set a “neutral” rating and a $200.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $228.91.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.